Related Experiment Video
Updated: Mar 17, 2026
Polyethyleneimine-coated Iron Oxide Nanoparticles as a Vehicle for the Delivery of Small Interfering RNA to Macrophages In Vitro and In Vivo
Published on: February 5, 2019
Blocking Interleukin-4 Receptor α Using Polyethylene Glycol Functionalized Superparamagnetic Iron Oxide Nanocarriers
Abjal Pasha Shaik1, Asma Sultana Shaik2, Ali Al Majwal3
1Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Saud University, Riyadh, Saudi Arabia.
Purpose:
The specific targeting of interleukin-4 receptor α (IL4Rα) receptor offers a promising therapeutic approach for inhibition of tumor cell progression in breast cancer patients. In the current study, the in vitro efficacy of superparamagnetic iron oxide nanoparticles conjugated with anti-IL4Rα blocking antibodies (SPION-IL4Rα) via polyethylene glycol polymers was evaluated in 4T1 breast cancer cells.
Materials And Methods:
Cell viability, reactive oxygen species generation, and apoptosis frequency were assessed in vitro in 4T1 cancer cell lines following exposure to SPION-IL4Rα alone or combined with doxorubicin. In addition, immunofluorescence assessments and fluorimetrywere performed to confirm the specific targeting and interaction of the developed nanocarriers with IL4Rα receptors in breast cancer cells.
Results:
Blocking of IL4Rα receptors caused a significant decrease in cell viability and induced apoptosis in 4T1 cells. In addition, combined treatment with SPION-IL4Rα+doxorubicin caused significant increases in cell death, apoptosis, and oxidative stress compared to either SPION-IL4Rα or doxorubicin alone, indicating the enhanced therapeutic efficacy of this combination. The decrease in fluorescence intensity upon immunofluorescence and fluorimetry assays combined with increased viability and decreased apoptosis following the blocking of IL4Rα receptors confirmed the successful binding of the synthesized nanocarriers to the target sites on murine 4T1 breast cancerous cells.
Conclusion:
These results suggest that SPION-IL4Rα nanocarriers might be used for successfulreduction of tumor growth and inhibition of progression of metastasis in vivo.
Insights
Superparamagnetic iron oxide nanoparticles conjugated with anti-IL4Rα antibodies effectively target and inhibit breast cancer cell progression. Combination therapy with doxorubicin significantly enhances cell death and oxidative stress, suggesting potential for tumor growth reduction.
Area of Science:
- Nanomedicine and Drug Delivery
- Cancer Therapeutics
- Molecular Targeting
Background:
- Interleukin-4 receptor alpha (IL4Rα) is a potential therapeutic target for inhibiting breast cancer progression.
- Superparamagnetic iron oxide nanoparticles (SPIONs) offer a platform for targeted drug delivery.
- Developing targeted nanocarriers is crucial for enhancing therapeutic efficacy and reducing side effects in cancer treatment.
Purpose of the Study:
- To evaluate the in vitro efficacy of SPIONs conjugated with anti-IL4Rα blocking antibodies (SPION-IL4Rα) for breast cancer therapy.
- To assess the synergistic effect of SPION-IL4Rα combined with doxorubicin in 4T1 breast cancer cells.
- To confirm the specific targeting and interaction of SPION-IL4Rα with IL4Rα receptors on cancer cells.
Main Methods:
- In vitro assessment of cell viability, reactive oxygen species (ROS) generation, and apoptosis in 4T1 cells.
- Treatment groups included SPION-IL4Rα alone, doxorubicin alone, and the combination of SPION-IL4Rα + doxorubicin.
- Immunofluorescence and fluorimetry assays were employed to verify the specific binding of nanocarriers to IL4Rα receptors.
Main Results:
- Blocking IL4Rα receptors with SPION-IL4Rα significantly reduced cell viability and induced apoptosis in 4T1 cells.
- The combination of SPION-IL4Rα and doxorubicin demonstrated enhanced therapeutic efficacy, leading to increased cell death, apoptosis, and oxidative stress.
- Assays confirmed successful binding of SPION-IL4Rα to IL4Rα receptors on murine 4T1 breast cancer cells, validated by decreased fluorescence intensity.
Conclusions:
- SPION-IL4Rα nanocarriers show promise for targeted inhibition of breast cancer cell progression.
- The combination therapy exhibits enhanced efficacy, suggesting a potential strategy for reducing tumor growth.
- These findings support the potential of SPION-IL4Rα for in vivo applications in reducing tumor growth and metastasis.
